Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy

[21] Ingles A(2018)Role of cytoreductive nephrectomy in the targeted therapy era: a systematic review and meta-analysis Investig Clin Urol 59 2-482

[22] Bamias A(2018)Cytoreductive nephrectomy - patient selection is key N Engl J Med 379 481-196

[23] Tzannis K(2010)Profile of temsirolimus in the treatment of advanced renal cell carcinoma Onco Targets Ther 3 191-v649

[24] Papatsoris A(2017)Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME) Ann Oncol 28 v605-21

[25] Xiao WJ(2015)Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes Nat Genet 47 13-145

[26] Zhu Y(2016)Comprehensive molecular characterization of papillary renal-cell carcinoma N Engl J Med 374 135-49

[27] Dai B(2013)Comprehensive molecular characterization of clear cell renal cell carcinoma Nature 499 43-1813

[28] Zhang HL(2015)Nivolumab versus Everolimus in advanced renal-cell carcinoma N Engl J Med 373 1803-1290

[29] Ye DW(2018)Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma N Engl J Med 378 1277-undefined

[30] Abern MR(undefined)undefined undefined undefined undefined-undefined

[21] Ingles A(2018)Role of cytoreductive nephrectomy in the targeted therapy era: a systematic review and meta-analysis Investig Clin Urol 59 2-482

[22] Bamias A(2018)Cytoreductive nephrectomy - patient selection is key N Engl J Med 379 481-196

[23] Tzannis K(2010)Profile of temsirolimus in the treatment of advanced renal cell carcinoma Onco Targets Ther 3 191-v649

[24] Papatsoris A(2017)Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME) Ann Oncol 28 v605-21

[25] Xiao WJ(2015)Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes Nat Genet 47 13-145

[26] Zhu Y(2016)Comprehensive molecular characterization of papillary renal-cell carcinoma N Engl J Med 374 135-49

[27] Dai B(2013)Comprehensive molecular characterization of clear cell renal cell carcinoma Nature 499 43-1813

[28] Zhang HL(2015)Nivolumab versus Everolimus in advanced renal-cell carcinoma N Engl J Med 373 1803-1290

[29] Ye DW(2018)Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma N Engl J Med 378 1277-undefined

[30] Abern MR(undefined)undefined undefined undefined undefined-undefined